Welcome to our dedicated page for Autonomix Medical news (Ticker: AMIX), a resource for investors and traders seeking the latest updates and insights on Autonomix Medical stock.
Autonomix Medical, Inc. develops precision nerve-targeted medical device technology for diagnosing and treating diseases involving the nervous system. The company’s platform includes a catheter-based microchip sensing array intended to detect and differentiate neural signals and support transvascular approaches to peripheral nerve identification and treatment.
Recurring AMIX news centers on clinical and scientific updates for transvascular radiofrequency energy-based ablation, including pain mitigation research in pancreatic adenocarcinoma and peripheral nerve modulation. Company announcements also cover medical and interventional conference presentations, abstract selections, publication strategy, corporate presentations, and the clinical validation process for its minimally invasive nerve-targeted platform.
Autonomix Medical (NASDAQ: AMIX) announced that two scientific abstracts featuring its transvascular nerve-targeting technology have been accepted for poster presentation at the CIRSE 2026 Annual Congress, held September 5-9, 2026, in Copenhagen, Denmark.
Both posters, presented by Dr. Robert Schwartz, address pain mitigation in pancreatic adenocarcinoma via transvascular RF ablation and the use of precision-guided transvascular technology for nervous system mapping, aligning with CIRSE’s theme of expanding access to minimally invasive, image-guided care.
Autonomix Medical (NASDAQ: AMIX) announced the issuance of U.S. Patent No. 12,714,780 on August 25, 2026, covering systems that integrate real-time physiological feedback, sensing and imaging with controlled delivery of therapeutic agents.
The patent protects medical systems using surgical instruments and controllers to regulate treatment based on feedback signals from targeted or surrounding tissues, including control of therapeutic fluid quantity and distribution. It encompasses applications where targeted tissue includes tumors and therapeutic fluids enable neural ablation to reduce cancer pain, and covers denervating and neuroblocking agents. The patent also addresses monitoring, imaging, stimulating and ablating neurological structures in the lower urinary tract via minimally invasive access routes, and is based on continuation applications dating back to 2012 and 2014.
Autonomix Medical (NASDAQ: AMIX) entered a warrant inducement agreement with an investor for the immediate cash exercise of July 2026 warrants to purchase 857,462 shares at $5.75 per share. The resale of these shares is covered by an effective Form S-3 registration statement.
Autonomix expects approximately $4.9 million in gross proceeds before fees. In return, the investor will receive unregistered Series E-1 and Series E-2 warrants, each for 535,913 shares, exercisable immediately at $6.25 per share and expiring five years after issuance. Closing is expected on or about August 26, 2026, subject to customary conditions.
Autonomix Medical (NASDAQ: AMIX) reported completion of a Good Laboratory Practice (GLP) preclinical study of its nerve-targeted medical device platform in porcine models, described as a significant regulatory milestone toward a planned submission to the U.S. Food and Drug Administration (FDA).
The study, run under FDA GLP standards, assessed safety, functionality and performance across multiple clinically relevant anatomical targets. Final histopathology and laboratory analyses were said to support previously reported positive safety and performance outcomes. Autonomix expects these data to form a key component of its regulatory package and to support future FDA submissions as it progresses from preclinical development toward clinical-stage execution.
Autonomix Medical (NASDAQ: AMIX) announced that its Co-Founder and Chief Medical Officer, Dr. Robert Schwartz, has been selected to receive the 2026 Cardiovascular Tech Forum (CTF) Lifetime Achievement Award. The honor recognizes his long-standing contributions to cardiovascular medicine, medical technology innovation and entrepreneurial leadership.
Dr. Schwartz will be formally honored at Octane’s 2026 Cardiovascular Tech Forum on September 18, 2026, in Newport Beach, California. According to Autonomix, he has authored more than 500 scientific publications, holds over 200 patents, and has founded multiple medtech companies, including co-inventing the Watchman device, later acquired by Boston Scientific. Autonomix highlights that his experience supports the company’s efforts to advance precision nerve-targeted treatments.
Autonomix Medical (NASDAQ: AMIX) announced issuance of U.S. Patent No. 12,433,670, titled “Systems and Methods for Treating Cancer and/or Augmenting Organ Function.” The patent expands protection for minimally invasive technologies that sense, map and selectively target nerves linked to tumors, cancer-related pain, organ function and autonomic nervous system disorders.
The patent covers catheter-based microsurgical tools that record neural signals and deliver energy or therapeutic agents to block or modulate identified nerves. According to Autonomix Medical, it broadens the company’s precision neuromodulation platform and complements previously issued patents in autonomic assessment, neural sensing, treatment guidance and transvascular neuromodulation.
Autonomix Medical (NASDAQ: AMIX) reported positive preclinical results showing its proprietary neural sensing platform can detect, localize and confirm changes in renal neural activity in an animal model. The endovascular Autonomix catheter was positioned in renal arteries, where researchers recorded neural signals across multiple anatomical locations and observed consistent activity patterns.
After targeted ablation, the team observed attenuation of previously detected neural signals, indicating the platform may both identify neural targets and assess changes in neural activity following therapy. According to Autonomix Medical, these findings support continued development of physiology-guided renal denervation procedures that provide direct physiological feedback, potentially enabling more precise, patient-specific treatment for conditions such as resistant hypertension. The company plans additional preclinical and future clinical studies to further evaluate neural sensing in renal denervation.
Autonomix Medical (NASDAQ: AMIX) announced the issuance of U.S. Patent No. 12,471,776, titled “ANS Assessment Systems, Kits, and Methods,” which broadens protection for its autonomic nervous system (ANS) assessment technologies. The patent covers systems, devices and methods for monitoring physiologic signals to evaluate sympathetic and parasympathetic nervous system activity using multiple assessment techniques.
According to Autonomix, the intellectual property may support patient selection, procedural guidance, treatment feedback and post-treatment monitoring across a wide range of neuromodulation applications. The patented systems use advanced imaging, sensors and algorithms to analyze ANS activity and are aimed at precision-based diagnosis and treatment of diseases involving the peripheral nervous system, further expanding the company’s neuromodulation-focused IP portfolio.
Autonomix Medical (NASDAQ: AMIX) announced issuance of U.S. Patent No. 12,611,134 for “Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder,” expanding its neural sensing and therapeutic platform into urology. The patent covers a catheter-based, minimally invasive system for bladder-wall nerve mapping and targeted therapies, including radiofrequency, thermal, ultrasonic energy and localized drug delivery. It also includes an implantable device for long-term monitoring and potential sustained local drug release. According to Autonomix Medical, this adds to a portfolio of 112 issued or pending patents worldwide, with protections extending into the late 2030s, supporting multi-organ, organ-specific applications from a single core technology.
Autonomix Medical (NASDAQ: AMIX) entered a warrant inducement agreement with an existing investor for the immediate cash exercise of November 19, 2025 warrants covering 428,731 shares of common stock at an amended exercise price of $6.00 per share, expected to generate approximately $2.6 million in gross proceeds before fees.
In return, Autonomix Medical will issue the investor unregistered Series D-1 and Series D-2 warrants, each for 428,731 shares, at a $5.75 exercise price, exercisable immediately and expiring five and a half years after issuance. The closing is expected around July 15, 2026, and the company plans to register the resale of shares underlying the new warrants.